Literature DB >> 15862929

Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors.

Filippo Cremonini1, Nicholas J Talley.   

Abstract

IBS is a common condition, affecting approximately 3% to 15% of the general population based on various diagnostic criteria. There seem to be differences in disease epidemiology between the eastern and the western world. As data from larger Asian epidemiological studies begin to surface,however, such differences appear to be less marked. The proportion of IBS patients who consult a physician for their symptoms is around 50%. Psychological factors and the presence and duration of abdominal pain are all significant predictors for health care seeking. The natural history of IBS is characterized by frequent fluctuation of symptoms and by an overlap with other functional GI disorders, some of which share a number of risk factors for IBS. Unnecessary abdominal surgery is performed in a high proportion of IBS sufferers. Along with the established role for psychosocial conditions in IBS, other risk factors are emerging. Evidence for postinfectious IBS is mounting, but the clinical usefulness of characterizing such patients remains unclear. Food sensitivities are frequently present in IBS, but more well-conducted trials of avoidance diets and desensitization are needed. Finally,genetic markers in IBS are an increasing focus of attention, but the amount of phenotypic variance explained by genetic variability remains to be established.

Entities:  

Mesh:

Year:  2005        PMID: 15862929     DOI: 10.1016/j.gtc.2005.02.008

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  58 in total

1.  Analgesic effect of Coptis chinensis rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome.

Authors:  Yungwui Tjong; Siupo Ip; Lixing Lao; Harry H S Fong; Joseph J Y Sung; Brian Berman; Chuntao Che
Journal:  J Ethnopharmacol       Date:  2011-04-12       Impact factor: 4.360

2.  The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients.

Authors:  Yuyuan Li; Yuqiang Nie; Jun Xie; Weizhan Tang; Peizhi Liang; Weihong Sha; Hui Yang; Yonyjian Zhou
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

3.  High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease.

Authors:  Jee-Yon Lee; Stephanie A Cevallos; Mariana X Byndloss; Connor R Tiffany; Erin E Olsan; Brian P Butler; Briana M Young; Andrew W L Rogers; Henry Nguyen; Kyongchol Kim; Sang-Woon Choi; Eunsoo Bae; Je Hee Lee; Ui-Gi Min; Duk-Chul Lee; Andreas J Bäumler
Journal:  Cell Host Microbe       Date:  2020-07-14       Impact factor: 21.023

4.  Development and pilot testing of an integrated, web-based self-management program for irritable bowel syndrome (IBS).

Authors:  S D Dorn; O S Palsson; M Woldeghebriel; B Fowler; R McCoy; M Weinberger; D A Drossman
Journal:  Neurogastroenterol Motil       Date:  2014-12-06       Impact factor: 3.598

Review 5.  Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review.

Authors:  Jun Shi; Yao Tong; Jian-Gang Shen; Hai-Xia Li
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

6.  Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions.

Authors:  Spencer D Dorn; Joel F Farley; Richard A Hansen; Nilay D Shah; Robert S Sandler
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

7.  Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population.

Authors:  F Cremonini; M Camilleri; A R Zinsmeister; L M Herrick; T Beebe; N J Talley
Journal:  Neurogastroenterol Motil       Date:  2008-09-18       Impact factor: 3.598

8.  Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?

Authors:  Savio C Reddymasu; Sandra Sostarich; Richard W McCallum
Journal:  BMC Gastroenterol       Date:  2010-02-22       Impact factor: 3.067

9.  Probiotic treatment of irritable bowel syndrome in children.

Authors:  U Martens; P Enck; E Zieseniss
Journal:  Ger Med Sci       Date:  2010-03-02

10.  Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes.

Authors:  Ami D Sperber; Roy Dekel
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.